Acetylsalicylic acid/dipyridamole

Acetylsalicylic acid/dipyridamole
Combination of
Acetylsalicylic acid Antithrombotic
Dipyridamole Antithrombotic
Clinical data
Trade names Aggrenox, Asasantin
AHFS/ UK Drug Information
Routes of
ATC code B01AC30 (WHO)
CAS Number 87653-67-6
PubChem (CID) 137329
ChemSpider 121018

The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[1]

The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events such as stroke.[3] Its use has been shown to be better than the use of either dipyridamole or aspirin alone.[4]


  1. FASS (the Swedish official drug catalog) > Asasantin Last update: 2009–08–17
  2. "Dipyridamole" at Dorland's Medical Dictionary
  3. Malinin, Alex I.; Eisert, Roswith M.; Atar, Dan; Barkagan, Zinoviy; Serebruany, Victor L. (2002). "Aggrenox® (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events". Heart Drug. 2 (2): 93–104. doi:10.1159/000063427.
  4. Serebruany, Victor L.; Malinin, Alex I.; Sane, David C.; Jilma, Bernd; Takserman, Aviv; Atar, Dan; Hennekens, Charles H. (September 2004). "Magnitude and time course of platelet inhibition with Aggrenox® and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial". European Journal of Pharmacology. 499 (3): 315–324. doi:10.1016/j.ejphar.2004.07.114.
This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.